52,849 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Acquired by Aristides Capital LLC

Aristides Capital LLC purchased a new position in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 52,849 shares of the biotechnology company’s stock, valued at approximately $81,000.

Several other institutional investors also recently modified their holdings of HRTX. Nicolet Advisory Services LLC bought a new stake in shares of Heron Therapeutics during the 4th quarter worth $25,000. Argent Advisors Inc. acquired a new position in shares of Heron Therapeutics in the 4th quarter valued at $31,000. Y Intercept Hong Kong Ltd purchased a new position in Heron Therapeutics in the 3rd quarter worth about $39,000. Cutter & CO Brokerage Inc. increased its stake in Heron Therapeutics by 69.6% in the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 13,600 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Heron Therapeutics during the 3rd quarter worth about $72,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

Shares of HRTX opened at $1.96 on Tuesday. The business’s 50-day moving average is $2.05 and its 200-day moving average is $1.79. The company has a market capitalization of $298.57 million, a price-to-earnings ratio of -10.89 and a beta of 1.39. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. Equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HRTX shares. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, February 28th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.